SCHEMBL3296193

SCHEMBL3296193

COc1cc(NC(=O)c2ccc(-c3ccccc3)cc2)ccc1C(=O)O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 11/20 0.69
TRPV1 Q8NER1 1/20 0.62
SMN1; SMN2 Q16637 2/20 0.60
KDM4E B2RXH2 1/20 0.60
MEN1 O00255 1/20 0.60
LMNA P02545 1/20 0.60
MAPT P10636 1/20 0.60
KMT2A Q03164 1/20 0.60
ABCC1 P33527 1/20 0.60
ADORA3 P0DMS8 1/20 0.59
HTR2C P28335 1/20 0.58
GALK1 P51570 1/20 0.58
CASP6 P55212 1/20 0.58
MCL1 Q07820 1/20 0.58
PLEC Q15149 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
PTPN1 P18031 1/20 0.57
CYP1A2 P05177 1/20 0.56
POLB P06746 1/20 0.56
CYP3A4 P08684 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18030845 0.90 NR1H4 (0.67) MCHR1TRPV1SMN1; SMN2KDM4EMEN1
SCHEMBL18007317 0.84 ABCC1 (0.63) MCHR1TRPV1KDM4EMEN1LMNA
SCHEMBL18007316 0.83 KDM4E (0.73) MCHR1TRPV1SMN1; SMN2KDM4EMEN1
SCHEMBL6993091 0.83 HTT (0.73) KDM4ELMNAMAPTKMT2APOLB
SCHEMBL4246500 0.82 KDM4E (0.64) MCHR1SMN1; SMN2KDM4EMEN1LMNA
SCHEMBL18030750 0.82 KDM4E (0.65) MCHR1TRPV1SMN1; SMN2KDM4EMEN1
SCHEMBL18030783 0.82 KDM4E (0.65) MCHR1TRPV1SMN1; SMN2KDM4EMEN1
SCHEMBL7417220 0.82 HTT (0.71) KDM4ELMNAMAPTKMT2APOLB
SCHEMBL6108921 0.82 MCHR1 (1.00) MCHR1TRPV1HTR2C
SCHEMBL16098149 0.82 TRPV1 (0.62) MCHR1TRPV1SMN1; SMN2KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060173058-A1 Kcnq channel modulating compounds and their pharmaceutical use NEUROSEARCH A/S (DK) 2006-08-03 US claimed
EP-1603858-A2 KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE NeuroSearch A/S (DK) 2005-12-14 EP claimed
WO-2004080377-A2 KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE NEUROSEARCH A/S (DK) 2004-09-23 WO claimed
US-7741352-B2 KCNQ channel modulating compounds and their pharmaceutical use NEUROSEARCH A/S (DK) 2010-06-22 US disclosed
US-7741352-B2 KCNQ channel modulating compounds and their pharmaceutical use NEUROSEARCH A/S (DK) 2010-06-22 US disclosed
US-7741352-B2 KCNQ channel modulating compounds and their pharmaceutical use NEUROSEARCH A/S (DK) 2010-06-22 US disclosed
US-20060173058-A1 Kcnq channel modulating compounds and their pharmaceutical use NEUROSEARCH A/S (DK) 2006-08-03 US disclosed
EP-1603858-A2 KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE NeuroSearch A/S (DK) 2005-12-14 EP disclosed
WO-2004080377-A2 KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE NEUROSEARCH A/S (DK) 2004-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060173058-A1 Kcnq channel modulating compounds and their pharmaceutical use KCNQ1, KCNQ2, KCNQ5 MCHR1 2534/4885TRPV1 96/4885SMN1; SMN2 2692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.